ArticleBiochemical and biophysical research communications2013
CITED2 modulates estrogen receptor transcriptional activity in breast cancer cells.
Article in Biochemical and biophysical research communications, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 25 citations in OpenAlex.
- Identification of genomic features that uniquely impact estrogen receptor alpha binding and its effects on gene expression in endometrial cancer.Genome research · 2026Article
- Identification of genomic features that uniquely impact estrogen receptor alpha binding and its effects on gene expression in endometrial cancer.bioRxiv : the preprint server for biology · 2026Article
- Super-Enhancer Target Gene CBP/p300-Interacting Transactivator With Glu/Asp-Rich C-Terminal Domain, 2 Cooperates With Transcription Factor Forkhead Box J3 to Inhibit Pulmonary Vascular Remodeling.Cell proliferation · 2025Article
- Cited2 is a key regulator of placental development and plasticity.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024Review
- Screening Preeclampsia Genes and the Effects of CITED2 on Trophoblastic Function.International journal of general medicine · 2024Article
- Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases.Signal transduction and targeted therapy · 2023Review
- CITED2 inhibits STAT1-IRF1 signaling and atherogenesis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
- Role of CITED2 in stem cells and cancer.Oncology letters · 2020Review
- CITED2 and the modulation of the hypoxic response in cancer.World journal of clinical oncology · 2020Review
- Article
- Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome.Breast cancer research and treatment · 2019Article
- An estrogen receptor (ER)-related signature in predicting prognosis of ER-positive breast cancer following endocrine treatment.Journal of cellular and molecular medicine · 2019Article
- Integrative Analysis Reveals Subtype-Specific Regulatory Determinants in Triple Negative Breast Cancer.Cancers · 2019Article
- Cited4 is a sex-biased mediator of the antidiabetic glitazone response in adipocyte progenitors.EMBO molecular medicine · 2018Article
- CITED2 attenuates macrophage recruitment concordant with the downregulation of CCL20 in breast cancer cells.Oncology letters · 2018Article
- Progesterone signalling in broiler skeletal muscle is associated with divergent feed efficiency.BMC systems biology · 2017Article
- Down-regulation of CITED2 attenuates breast tumor growth, vessel formation and TGF-β-induced expression of VEGFA.Oncotarget · 2017Article
- CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance.Cancer science · 2016Article
- CITED2 Modulates Breast Cancer Metastatic Ability through Effects on IKKα.Molecular cancer research : MCR · 2016Article
- RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines.International journal of clinical and experimental pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 (CITED2) is a member of the CITED family of non-DNA binding transcriptional co-activators of the p300/CBP-mediated transcription complex. Previously, we identified CITED2 as being overexpressed in human breast tumors relative to normal mammary epithelium. Upon further investigation within the estrogen receptor (ER)-positive subset of these breast tumor samples, we found that CITED2 mRNA expression was elevated in those associated with poor survival. In light of this observation, we investigated the effect of elevated CITED2 levels on ER function. While ectopic overexpression of CITED2 in three ER-positive breast cancer cell lines (MCF-7, T47D, and CAMA-1) did not alter cell proliferation in complete media, growth was markedly enhanced in the absence of exogenous estrogen. Correspondingly, cells overexpressing CITED2 demonstrated reduced sensitivity to the growth inhibitory effects of the selective estrogen receptor modulator, 4-hydroxytamoxifen. Subsequent studies revealed that basal ER transcriptional activity was elevated in CITED2-overexpressing cells and was further increased upon the addition of estrogen. Similarly, basal and estrogen-induced expression of the ER-regulated genes trefoil factor 1 (TFF1) and progesterone receptor (PGR) was higher in cells overexpressing CITED2. Concordant with this observation, ChIP analysis revealed higher basal levels of CITED2 localized to the TFF-1 and PGR promoters in cells with ectopic overexpression of CITED2, and these levels were elevated further in response to estrogen stimulation. Taken together, these data indicate that CITED2 functions as a transcriptional co-activator of ER in breast cancer cells and that its increased expression in tumors may result in estrogen-independent ER activation, thereby reducing estrogen dependence and response to anti-estrogen therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.